01—Abstract
Summary
Summary of the 8-K filed March 24, 2026. Cited figures are marked; the original filing is the authoritative source.
On March 24, 2026, Thermo Fisher Scientific (NYSE: TMO) disclosed in an 8-K (Item 8.01, with press release Exhibit 99.1) that it has completed its acquisition of Clario Holdings, Inc., a provider of endpoint data solutions for clinical trials.
The headline purchase price is $8.875 billiona in cash at closing. Thermo Fisher also agreed to pay $125 million in January 2027 and up to $400 million in earn-out payments tied to Clario's performance in 2026 and 2027, so total consideration could exceed the closing price if milestones are met. Clario will be integrated into the Laboratory Products and Biopharma Services segment.
The seller group was led by Astorg and Nordic Capital, with Novo Holdings and Cinven also among the sellers. Management characterizes the deal as strategically complementary to Thermo Fisher's clinical research offerings and reports a double-digit internal rate of return. Clario is expected to grow in the high single digits and to be accretive to adjusted operating margin.
Management expects the business to contribute $0.45b of adjusted EPS in the first year after close, with synergies of approximately $175 million of adjusted operating income by year five, primarily from revenue synergies. Detailed 2026 financial impact is deferred to the first-quarter 2026 earnings call. The filing contains no GAAP earnings guidance for the transaction, and the release notes that adjusted measures exclude acquisition-related items and amortization.
For investors, the key points are the size of the cash outlay relative to Thermo Fisher's scale (annual revenue above $40 billionc), the contingent payments that add to the total cost, and the reliance on revenue synergies to reach the stated return. The release also flags standard integration and forward-looking risks, including possible failure to realize expected benefits, customer and employee disruption at Clario, and difficulty retaining key staff.
02—Key points
Key Highlights
- Completed the acquisition of Clario Holdings, Inc., a provider of endpoint data solutions for clinical trials, for $8.875 billion in cash at closing
- Additional consideration includes $125 million payable in January 2027 and up to $400 million in earn-outs tied to 2026 and 2027 performance
- Clario will become part of the Laboratory Products and Biopharma Services segment
- Management expects Clario to contribute $0.45 of adjusted EPS in the first year after close and to grow in the high single digits
- Expected synergies of approximately $175 million of adjusted operating income by year five, primarily from revenue synergies
- Management cites a double-digit internal rate of return and accretion to adjusted operating margin
- Detailed 2026 financial impact will be provided on the first-quarter 2026 earnings call
03—Questions
Frequently Asked Questions
How much did Thermo Fisher pay for Clario?
Thermo Fisher paid $8.875 billion in cash at closing. It also agreed to pay $125 million in January 2027 and up to $400 million in earn-out payments based on Clario's performance in 2026 and 2027, so total consideration could be higher than the closing amount.
What does Clario do and where does it fit within Thermo Fisher?
Clario is a provider of endpoint data solutions for clinical trials, collecting and analyzing clinical evidence from devices, sites, and patients. Its platform has supported about 70% of FDA and EMA novel drug approvals over the past decade. Clario will be part of the Laboratory Products and Biopharma Services segment and complements Thermo Fisher's clinical research offerings.
How much will Clario add to Thermo Fisher's earnings?
Management previously said Clario is expected to contribute $0.45 of adjusted EPS in the first year after close. Adjusted EPS is a non-GAAP measure. The company will provide more detail on the 2026 impact on its first-quarter earnings call.
What synergies does Thermo Fisher expect from the deal?
Thermo Fisher continues to expect about $175 million of adjusted operating income from synergies by year five after closing. Most of the synergies are expected to come from revenue opportunities that the combined capabilities will unlock, rather than cost cuts.
What are the main risks to the deal?
The filing's forward-looking statements cite the possibility that expected benefits may not materialize, disruption to Clario's business from the transaction, difficulty retaining key employees, and challenges in integrating operations and achieving synergies on schedule. The company gives no assurance that its expectations will be met.
04—Continue